

# Texas Vaccine Providers Webinar Highlights – January 11, 2022

Read below for topics covered or view the [full recording](#) for detailed information.

## COVID-19 Vaccine Updates

- The CDC recently updated its website to include the following COVID-19 vaccine terminology changes:
  - *Additional dose* is now referred to as [additional primary dose](#).
  - CDC recommends that people remain [up to date](#) with their vaccines, which includes [additional doses](#) for individuals who are immunocompromised or [booster doses](#) at regular time points. Individuals who are [moderately or severely immunocompromised](#) should get an additional primary shot and a booster shot.
- Access DSHS’ new COVID-19 Vaccination Recommendations chart, which includes information on dosing for each COVID-19 vaccine formulation, [here](#).
- The CDC provides guidance for people vaccinated outside the United States in the “[People who received COVID-19 vaccine outside the United States](#)” section of the [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#) webpage.
- Providers are reminded to take all opportunities to co-administer the COVID-19 vaccine with other vaccines. For more information about co-administration, see the [CDC co-administration guidelines](#).

## COVID-19 Vaccine Resources

- Providers are highly encouraged to reference the CDC’s [Interim Clinical Considerations](#) when questions arise. These considerations apply only to the use of vaccine products currently approved or authorized in the United States and are updated when additional information becomes available or if additional vaccine products are approved or authorized. If you cannot find the answer to your question in the [Interim Clinical Considerations](#), consider directing your clinical questions to the Texas DSHS COVID-19 Nurse Call Center (phone: 833-832-7068, option 4; email: [CoronaVirus@dshs.Texas.gov](mailto:CoronaVirus@dshs.Texas.gov)). Providers can also request a consultation from the Clinical Immunization Safety Assessment (CISA) COVIDvax through **CDC-INFO** by calling 800-232-4636.

## Product Ordering Updates

- When submitting a COVID-19 vaccine transfer request in the Vaccine Allocation & Ordering System (VAOS), please ensure that you select **the same vaccine type and presentation for the inventory record**.
- Providers receiving transfers through Health Hero can expect to their **inventory to be updated within VAOS the Monday after receiving their vaccine**. Providers are encouraged to **wait** to use the transferred vaccines until after their inventory has been updated.

## Provider Resources:

- [COVID-19 Vaccine Management Resources \(training and support materials\)](#)
- [ImmTrac2 User Training Site](#)
- [ImmTrac2 Forms and Documents](#)
- [COVID-19 Vaccine Provider Enrollment Information](#)
- [CDC Clinical Considerations for or Use of mRNA COVID-19 Vaccines](#)
- DSHS Provider Help Desk: (833) 832-7068, 8 a.m. to 5 p.m., Monday through Friday; Email: [COVID19VacEnroll@dshs.texas.gov](mailto:COVID19VacEnroll@dshs.texas.gov)

## Live Q&A:

**Below are a sample of the questions DSHS subject matter experts answered during the 1/11 webinar’s live Q&A session.**

- Can immunocompromised individuals receive an additional primary dose *after* receiving a booster dose?
- Do the phrases “up to date” and “fully vaccinated” have different meanings?
- Are there any differences in dosing in clients 5-17 years of age vs. 18+ years of age? Do we need to use different formulations of COVID-19 vaccine?
- If a client received 2 doses of Moderna COVID-19 vaccines for their primary series, can they receive a Pfizer booster 5 months or 6 months after completing the Moderna primary series?

